Annals of Surgical Oncology

, Volume 18, Issue 9, pp 2594–2598 | Cite as

A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer

  • Yijun Chen
  • Kerry Kingham
  • James M. Ford
  • James Rosing
  • Jacques Van Dam
  • R. Brooke Jeffrey
  • Teri A. Longacre
  • Nicki Chun
  • Allison Kurian
  • Jeffrey A. NortonEmail author
Gastrointestinal Oncology



Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome. Up to 30% of families with HDGC have mutations in the E-cadherin gene, CDH1. The role of prophylactic versus therapeutic gastrectomy for HDGC was studied prospectively.


Eighteen consecutive patients with CDH1 mutations and positive family history were studied prospectively, including 13 without and 5 with symptoms. Proportions were compared by Fisher’s exact test, and survival by the Breslow modification of the Wilcoxon rank-sum test.


Each patient underwent total gastrectomy (TG), and 17 (94%) were found to have signet ring cell adenocarcinoma. Twelve of 13 asymptomatic patients had T1, N0 cancer, and only 2/12 (16%) had it diagnosed preoperatively despite state-of-the-art screening methods. Each asymptomatic patient did well postoperatively, and no patient has recurred. For five symptomatic patients, each (100%) was found to have signet ring cell adenocarcinoma (P = 0.002 versus asymptomatic) by preoperative endoscopy; three (60%) had lymph node involvement and two (40%) had distant metastases at time of operation. Two-year survival was 100% for asymptomatic and 40% for symptomatic patients (P < 0.01).


The data show that asymptomatic patients with family history of HDGC and CDH1 mutation have high probability of having signet ring cell adenocarcinoma of the stomach that is not able to be diagnosed on endoscopy; when symptoms arise, the diagnosis can be made by endoscopy, but they have metastases and decreased survival. Surveillance endoscopy is of limited value, and prophylactic gastrectomy (PG) is recommended for patients with family history of HDGC and CDH1 mutations.


Gastric Cancer Total Gastrectomy Signet Ring Cell Hereditary Diffuse Gastric Cancer CDH1 Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14 Suppl 2:ii31–6.PubMedGoogle Scholar
  2. 2.
    Dunbier A, Guilford P. Hereditary diffuse gastric cancer. Adv Cancer Res. 2001;83:55–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  4. 4.
    Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14:21–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508–17.PubMedCrossRefGoogle Scholar
  6. 6.
    Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Humar B, Guilford P. Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci. 2009;100:1151–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086–9.PubMedGoogle Scholar
  9. 9.
    Guilford PJ, Hopkins JB, Grady WM, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat. 1999;14:249–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999;8:607–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Shinmura K, Kohno T, Takahashi M, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis. 1999;20:1127–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Yoon KA, Ku JL, Yang HK, et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet. 1999;44:177–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Ghaffari SR, Rafati M, Sabokbar T, et al. A novel truncating mutation in the E-cadherin gene in the first Iranian family with hereditary diffuse gastric cancer. Eur J Surg Oncol. 2010;36:559–62.PubMedGoogle Scholar
  16. 16.
    Hebbard PC, Macmillan A, Huntsman D, et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol. 2009;16:1890–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245:873–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001;130:612–7; discussion 617–619.PubMedCrossRefGoogle Scholar
  19. 19.
    Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg. 2006;202:612–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010;13:1–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Cisco RM, Norton JA. Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions. Future Oncol. 2008;4:553–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Shaw D, Blair V, Framp A, et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut. 2005;54:461–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008;32:799–809.PubMedCrossRefGoogle Scholar
  24. 24.
    Barber ME, Save V, Carneiro F, et al. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol. 2008;216:286–94.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Yijun Chen
    • 1
  • Kerry Kingham
    • 5
    • 6
  • James M. Ford
    • 5
    • 6
  • James Rosing
    • 1
  • Jacques Van Dam
    • 3
  • R. Brooke Jeffrey
    • 4
  • Teri A. Longacre
    • 2
    • 4
  • Nicki Chun
    • 5
    • 6
  • Allison Kurian
    • 5
  • Jeffrey A. Norton
    • 1
    Email author
  1. 1.Departments of SurgeryStanford University School of Medicine, Stanford Comprehensive Cancer CenterStanfordUSA
  2. 2.Departments of PathologyStanford University School of Medicine, Stanford Comprehensive Cancer CenterStanfordUSA
  3. 3.Departments of GastroenterologyStanford University School of Medicine, Stanford Comprehensive Cancer CenterStanfordUSA
  4. 4.Departments of RadiologyStanford University School of Medicine, Stanford Comprehensive Cancer CenterStanfordUSA
  5. 5.Departments of MedicineStanford University School of Medicine, Stanford Comprehensive Cancer CenterStanfordUSA
  6. 6.Departments of GeneticsStanford University School of Medicine, Stanford Comprehensive Cancer CenterStanfordUSA

Personalised recommendations